We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Companion Animal Products Boost Lifts Dechra's Half-Year Profit

Mon, 22nd Feb 2021 08:28

(Alliance News) - Dechra Pharmaceuticals PLC on Monday reported a considerable increase in half-year profit, with particularly strong revenue growth from Companion Animal Products.

For the six months ended December 31, Dechra's pretax profit was GBP35.4 million, up 82% from GBP19.5 million the year before.

This was revenue increased to GBP299.8 million from GBP248.5 million the year before, with 21.7% European Pharmaceuticals revenue growth and 21.9% North American Pharmacueticals revenue growth at constant exchange rate, 23% and 17% respectively at actual exchange rate.

"Revenue growth has been strong, especially within Companion Animal Products, as pet ownership and welfare has become more important to people as the Covid-19 pandemic has changed peoples' way of living," Dechra noted.

Companion Animal Products revenue rose to GBP219.0 million from GBP173.7 million, 26% higher at AER and 27% higher at CER.

"The group also benefited from a significantly improved supply chain and a pre-Brexit inventory build. The strong revenue growth, good gross margin and lower than usual underlying selling, general and administrative costs, due to Covid-19 restricting activity, has resulted in a stronger than expected operating profit performance," the company added.

Dechra declared an 11.11 pence per share interim dividend, up 8.0% year-on-year from 10.29p.

In terms of outlook, Dechra said: "Trading in the second half remains robust, although we are starting to see the pre-Brexit inventory build unwind and, therefore, we expect the balance of trading to be first half weighted.

"Overall the outlook for the full year remains positive and in line with our January trading update. We expect the strong favourable market conditions to remain, our recent acquisitions to perform well and our supply chain improvement to continue. We continue to demonstrate our ability to execute our strategy so despite the ongoing challenges of the Covid-19 pandemic we remain confident in our future prospects."

Shares in Dechra were down 1.9% at 3,542.00 pence in London on Monday morning.

By Anna Farley; annafarley@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News
12 Jan 2024 06:59

IN BRIEF: Persimmon to replace outbound FTSE 100 constituent Dechra

Persimmon PLC - York, England-based housebuilder - To rejoin FTSE 100 index on Tuesday as acquisition of Cheshire, England-based veterinary drug maker...

27 Dec 2023 10:29

IN BRIEF: EU clears Dechra Pharmaceuticals takeover by EQT funds

Dechra Pharmaceuticals PLC - Cheshire, England-based veterinary drug maker - European Commission on Friday clears takeover of Dechra by funds managed ...

6 Dec 2023 15:13

UK shareholder meetings calendar - next 7 days

29 Nov 2023 09:19

IN BRIEF: Hargreaves Lansdown picks Dechra chair Alison Platt as chair

Hargreaves Lansdown PLC - Bristol, England-based wealth management platform - Hires Alison Platt, the current chair of Dechra Pharmaceuticals PLC, to ...

29 Nov 2023 08:26

LONDON MARKET OPEN: FTSE 100 falls; Halfords, Xaar plunge

(Alliance News) - Stock prices in London opened mixed on Wednesday, as large caps fell on account of a stronger pound, though the domestically-focused...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.